Superiority data from LATA together with OPERA findings add to the clinical and real-world evidence base for long-acting injectable Cabenuva
Investment further integrates company into world-class ecosystem of biomedical research, patient care and academia
ARTEMIS-011, a phase III study conducted for China, met its primary endpoint of progression-free survival in relapsed osteosarcoma
Positive Week 48 data from the phase IIIb VOGUE study reinforce Dovato as an effective treatment option with fewer medicines than Biktarvy
Next-generation design aims to address key efficacy and tolerability challenges of treating ROS1-positive NSCLC.
VOGUE is the first head-to-head, randomised daily orals study comparing 2-drug regimen Dovato with 3-drug regimen Biktarvy
If approved, a single booster dose could help protect individuals who were previously vaccinated with Bexsero
GSK plc (LSE/NYSE: GSK) today provides an update on the CALM-1 and CALM-2 phase III clinical trials
GSK plc today announced completion of its acquisition of Nuvalent, Inc. , a Boston-based clinical-stage biopharmaceutical company.
Results support potential for dostarlimab to eliminate the need for chemotherapy, radiation and surgery in some patients
ARTEMIS-008 met its primary endpoint of overall survival in advanced or relapsed small-cell lung cancer
Roy Jakobs will join the Board of the Company as a Non-Executive Director from 13 July 2026.
GSK plc today announced that Harmony Row Acquisition Co. has commenced a tender offer to purchase all of the shares of Nuvalent, Inc.
More than 3 million cases of cUTIs are treated annually in the US with up to a third of patients impacted by resistant infections.
VEXAS syndrome is a rare, life-threatening haemato-inflammatory condition with no approved treatments.
Acquisition expected to be accretive to sales & core operating profit in 2027 & core EPS in 2029 inclusive of synergies and reprioritisation
Pivotal B-Well data show a significant 19% functional cure in the overall study population and 26% in patients with lower viral activity.
GSK will present new data from its expanding oncology portfolio and pipeline at ASCO and EHA.